Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Leerink Partners Maintains Underperform on Moderna, Raises Price Target to $18

Author: Benzinga Newsdesk | November 21, 2025 09:37am

Leerink Partners analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $15 to $18.

Posted In: MRNA